From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis

With the accelerated development of next-generation sequencing (NGS), identified variants, and targeted therapies, clinicians who confront the complicated and multifarious genetic information may not effectively incorporate NGS-based circulating tumor DNA (ctDNA) analysis into routine patient care....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2019-08
Hauptverfasser: Peng, Rongxue, Zhang, Rui, Horan, Martin P, Zhou, Li, Chai, Sze Yee, Pillay, Nalishia, Tay, Kwang Hong, Badrick, Tony, Li, Jinming
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title The oncologist (Dayton, Ohio)
container_volume
creator Peng, Rongxue
Zhang, Rui
Horan, Martin P
Zhou, Li
Chai, Sze Yee
Pillay, Nalishia
Tay, Kwang Hong
Badrick, Tony
Li, Jinming
description With the accelerated development of next-generation sequencing (NGS), identified variants, and targeted therapies, clinicians who confront the complicated and multifarious genetic information may not effectively incorporate NGS-based circulating tumor DNA (ctDNA) analysis into routine patient care. Consequently, standardized ctDNA testing reports are of vital importance. In an effort to guarantee high-quality reporting performance, we conducted an investigation of the current detection and reporting practices for NGS-based ctDNA analysis. A set of simulated ctDNA samples with known variants at known allelic frequencies and a corresponding case scenario were distributed to 66 genetic testing laboratories for ctDNA analysis. Written reports were collected to evaluate the detection accuracy, reporting integrity, and information sufficiency using 21 predefined criteria. Current reporting practices for NGS-based ctDNA analysis were found to be far from satisfactory, especially regarding testing interpretation and methodological details. Only 42.4% of laboratories reported the results in complete concordance with the expected results. Moreover, 74.2% of reports only listed aberrations with direct and well-known treatment consequences for the tumor type in question. Genetic aberrations for which experimental agents and/or drug access programs are available may thus be overlooked. Furthermore, methodological details for the interpretation of results were missing from the majority of reports (87.9%). This proof-of-principle study suggests that the capacity for accurate identification of variants, rational interpretation of genotypes, comprehensive recommendation of potential medications, and detailed description of methodologies need to be further improved before ctDNA analysis can be formally implemented in the clinic. Accurate, comprehensive, and standardized clinical sequencing reports can help to translate complex genetic information into patient-centered clinical decisions, thereby shepherding precision oncology into daily practice. However, standards, guidelines, and quality requirements for clinical reports of next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) analysis are currently absent. By using a set of simulated clinical ctDNA samples and a corresponding case scenario, current practices were evaluated to identify deficiencies in clinical sequencing reports of ctDNA analysis. The recommendations provided here may serve as a roadmap for
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_31471456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31471456</sourcerecordid><originalsourceid>FETCH-pubmed_primary_314714563</originalsourceid><addsrcrecordid>eNqFj8tOwzAQRS0kRMvjF9D8QKSEJKCwK4UCm4JohNhVgzOJjGI7zDhAvoWfxeKxZjWLe869mh01z8qiSooqfZqpfZGXNM3KKj_ZU7M8K86yojydq88VewsbbzEYDY_IBl0QqP07cgP3TNqI8Q7unPa976ZzWDi4dW8kwXTRiZFv4YEGz8G4LhqoYxNB6xnW9BGSa3LEP-SGXkdyOnLJBQo1sDSsxx6_zXq0UblcL-IC9pMYOVS7LfZCR7_3QB2vrurlTTKMz5aa7cDGIk_bv2_yf4EvlzFYDg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Peng, Rongxue ; Zhang, Rui ; Horan, Martin P ; Zhou, Li ; Chai, Sze Yee ; Pillay, Nalishia ; Tay, Kwang Hong ; Badrick, Tony ; Li, Jinming</creator><creatorcontrib>Peng, Rongxue ; Zhang, Rui ; Horan, Martin P ; Zhou, Li ; Chai, Sze Yee ; Pillay, Nalishia ; Tay, Kwang Hong ; Badrick, Tony ; Li, Jinming</creatorcontrib><description>With the accelerated development of next-generation sequencing (NGS), identified variants, and targeted therapies, clinicians who confront the complicated and multifarious genetic information may not effectively incorporate NGS-based circulating tumor DNA (ctDNA) analysis into routine patient care. Consequently, standardized ctDNA testing reports are of vital importance. In an effort to guarantee high-quality reporting performance, we conducted an investigation of the current detection and reporting practices for NGS-based ctDNA analysis. A set of simulated ctDNA samples with known variants at known allelic frequencies and a corresponding case scenario were distributed to 66 genetic testing laboratories for ctDNA analysis. Written reports were collected to evaluate the detection accuracy, reporting integrity, and information sufficiency using 21 predefined criteria. Current reporting practices for NGS-based ctDNA analysis were found to be far from satisfactory, especially regarding testing interpretation and methodological details. Only 42.4% of laboratories reported the results in complete concordance with the expected results. Moreover, 74.2% of reports only listed aberrations with direct and well-known treatment consequences for the tumor type in question. Genetic aberrations for which experimental agents and/or drug access programs are available may thus be overlooked. Furthermore, methodological details for the interpretation of results were missing from the majority of reports (87.9%). This proof-of-principle study suggests that the capacity for accurate identification of variants, rational interpretation of genotypes, comprehensive recommendation of potential medications, and detailed description of methodologies need to be further improved before ctDNA analysis can be formally implemented in the clinic. Accurate, comprehensive, and standardized clinical sequencing reports can help to translate complex genetic information into patient-centered clinical decisions, thereby shepherding precision oncology into daily practice. However, standards, guidelines, and quality requirements for clinical reports of next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) analysis are currently absent. By using a set of simulated clinical ctDNA samples and a corresponding case scenario, current practices were evaluated to identify deficiencies in clinical sequencing reports of ctDNA analysis. The recommendations provided here may serve as a roadmap for the improved implementation of NGS-based ctDNA analysis in the clinic.</description><identifier>EISSN: 1549-490X</identifier><identifier>PMID: 31471456</identifier><language>eng</language><publisher>United States</publisher><ispartof>The oncologist (Dayton, Ohio), 2019-08</ispartof><rights>AlphaMed Press 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1476-3397</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31471456$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Rongxue</creatorcontrib><creatorcontrib>Zhang, Rui</creatorcontrib><creatorcontrib>Horan, Martin P</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><creatorcontrib>Chai, Sze Yee</creatorcontrib><creatorcontrib>Pillay, Nalishia</creatorcontrib><creatorcontrib>Tay, Kwang Hong</creatorcontrib><creatorcontrib>Badrick, Tony</creatorcontrib><creatorcontrib>Li, Jinming</creatorcontrib><title>From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>With the accelerated development of next-generation sequencing (NGS), identified variants, and targeted therapies, clinicians who confront the complicated and multifarious genetic information may not effectively incorporate NGS-based circulating tumor DNA (ctDNA) analysis into routine patient care. Consequently, standardized ctDNA testing reports are of vital importance. In an effort to guarantee high-quality reporting performance, we conducted an investigation of the current detection and reporting practices for NGS-based ctDNA analysis. A set of simulated ctDNA samples with known variants at known allelic frequencies and a corresponding case scenario were distributed to 66 genetic testing laboratories for ctDNA analysis. Written reports were collected to evaluate the detection accuracy, reporting integrity, and information sufficiency using 21 predefined criteria. Current reporting practices for NGS-based ctDNA analysis were found to be far from satisfactory, especially regarding testing interpretation and methodological details. Only 42.4% of laboratories reported the results in complete concordance with the expected results. Moreover, 74.2% of reports only listed aberrations with direct and well-known treatment consequences for the tumor type in question. Genetic aberrations for which experimental agents and/or drug access programs are available may thus be overlooked. Furthermore, methodological details for the interpretation of results were missing from the majority of reports (87.9%). This proof-of-principle study suggests that the capacity for accurate identification of variants, rational interpretation of genotypes, comprehensive recommendation of potential medications, and detailed description of methodologies need to be further improved before ctDNA analysis can be formally implemented in the clinic. Accurate, comprehensive, and standardized clinical sequencing reports can help to translate complex genetic information into patient-centered clinical decisions, thereby shepherding precision oncology into daily practice. However, standards, guidelines, and quality requirements for clinical reports of next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) analysis are currently absent. By using a set of simulated clinical ctDNA samples and a corresponding case scenario, current practices were evaluated to identify deficiencies in clinical sequencing reports of ctDNA analysis. The recommendations provided here may serve as a roadmap for the improved implementation of NGS-based ctDNA analysis in the clinic.</description><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFj8tOwzAQRS0kRMvjF9D8QKSEJKCwK4UCm4JohNhVgzOJjGI7zDhAvoWfxeKxZjWLe869mh01z8qiSooqfZqpfZGXNM3KKj_ZU7M8K86yojydq88VewsbbzEYDY_IBl0QqP07cgP3TNqI8Q7unPa976ZzWDi4dW8kwXTRiZFv4YEGz8G4LhqoYxNB6xnW9BGSa3LEP-SGXkdyOnLJBQo1sDSsxx6_zXq0UblcL-IC9pMYOVS7LfZCR7_3QB2vrurlTTKMz5aa7cDGIk_bv2_yf4EvlzFYDg</recordid><startdate>20190830</startdate><enddate>20190830</enddate><creator>Peng, Rongxue</creator><creator>Zhang, Rui</creator><creator>Horan, Martin P</creator><creator>Zhou, Li</creator><creator>Chai, Sze Yee</creator><creator>Pillay, Nalishia</creator><creator>Tay, Kwang Hong</creator><creator>Badrick, Tony</creator><creator>Li, Jinming</creator><scope>NPM</scope><orcidid>https://orcid.org/0000-0002-1476-3397</orcidid></search><sort><creationdate>20190830</creationdate><title>From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis</title><author>Peng, Rongxue ; Zhang, Rui ; Horan, Martin P ; Zhou, Li ; Chai, Sze Yee ; Pillay, Nalishia ; Tay, Kwang Hong ; Badrick, Tony ; Li, Jinming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_314714563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Rongxue</creatorcontrib><creatorcontrib>Zhang, Rui</creatorcontrib><creatorcontrib>Horan, Martin P</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><creatorcontrib>Chai, Sze Yee</creatorcontrib><creatorcontrib>Pillay, Nalishia</creatorcontrib><creatorcontrib>Tay, Kwang Hong</creatorcontrib><creatorcontrib>Badrick, Tony</creatorcontrib><creatorcontrib>Li, Jinming</creatorcontrib><collection>PubMed</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Rongxue</au><au>Zhang, Rui</au><au>Horan, Martin P</au><au>Zhou, Li</au><au>Chai, Sze Yee</au><au>Pillay, Nalishia</au><au>Tay, Kwang Hong</au><au>Badrick, Tony</au><au>Li, Jinming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2019-08-30</date><risdate>2019</risdate><eissn>1549-490X</eissn><abstract>With the accelerated development of next-generation sequencing (NGS), identified variants, and targeted therapies, clinicians who confront the complicated and multifarious genetic information may not effectively incorporate NGS-based circulating tumor DNA (ctDNA) analysis into routine patient care. Consequently, standardized ctDNA testing reports are of vital importance. In an effort to guarantee high-quality reporting performance, we conducted an investigation of the current detection and reporting practices for NGS-based ctDNA analysis. A set of simulated ctDNA samples with known variants at known allelic frequencies and a corresponding case scenario were distributed to 66 genetic testing laboratories for ctDNA analysis. Written reports were collected to evaluate the detection accuracy, reporting integrity, and information sufficiency using 21 predefined criteria. Current reporting practices for NGS-based ctDNA analysis were found to be far from satisfactory, especially regarding testing interpretation and methodological details. Only 42.4% of laboratories reported the results in complete concordance with the expected results. Moreover, 74.2% of reports only listed aberrations with direct and well-known treatment consequences for the tumor type in question. Genetic aberrations for which experimental agents and/or drug access programs are available may thus be overlooked. Furthermore, methodological details for the interpretation of results were missing from the majority of reports (87.9%). This proof-of-principle study suggests that the capacity for accurate identification of variants, rational interpretation of genotypes, comprehensive recommendation of potential medications, and detailed description of methodologies need to be further improved before ctDNA analysis can be formally implemented in the clinic. Accurate, comprehensive, and standardized clinical sequencing reports can help to translate complex genetic information into patient-centered clinical decisions, thereby shepherding precision oncology into daily practice. However, standards, guidelines, and quality requirements for clinical reports of next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) analysis are currently absent. By using a set of simulated clinical ctDNA samples and a corresponding case scenario, current practices were evaluated to identify deficiencies in clinical sequencing reports of ctDNA analysis. The recommendations provided here may serve as a roadmap for the improved implementation of NGS-based ctDNA analysis in the clinic.</abstract><cop>United States</cop><pmid>31471456</pmid><orcidid>https://orcid.org/0000-0002-1476-3397</orcidid></addata></record>
fulltext fulltext
identifier EISSN: 1549-490X
ispartof The oncologist (Dayton, Ohio), 2019-08
issn 1549-490X
language eng
recordid cdi_pubmed_primary_31471456
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; Wiley Online Library All Journals; PubMed Central
title From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A53%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20Somatic%20Variants%20Toward%20Precision%20Oncology:%20An%20Investigation%20of%20Reporting%20Practice%20for%20Next-Generation%20Sequencing-Based%20Circulating%20Tumor%20DNA%20Analysis&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Peng,%20Rongxue&rft.date=2019-08-30&rft.eissn=1549-490X&rft_id=info:doi/&rft_dat=%3Cpubmed%3E31471456%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31471456&rfr_iscdi=true